This Pharma Company Won’t Commit to Fairly Pricing a Zika Vaccine You Helped Pay For image

The Huffington Post, June 9, 2017
Alexander C. Kaufman, quoting Rachel E. Sachs (Academic Fellow Alumna)

Links

Read the Full Article

From the article:

“The incentives for any one company to raise its prices or engage in questionable conduct are quite high, while the incentives for the industry as a whole to corral and police its members are really quite difficult to see,” said Rachel Sachs, an associate law professor at Washington University in St. Louis. “The best thing the industry can do to help itself is to tie its own hands in some of these very public deals.”

To be sure, Sanofi has expressed sensitivity to concerns about price gouging. The company said it would cap price increases for its product at 5.4 percent this year, with a few exceptions. It also said it benchmarks prices to the national health expenditures growth projection, a figure calculated by the U.S. Department of Health and Human Services. The Institute for Clinical and Economic Review, a drug price watchdog, praised Sanofi’s multiple sclerosis drug alemtuzumab, sold under the brand name Lemtrada, as a “good value.” [...]

Read the full article here

health care reform health law policy pharmaceuticals public health rachel sachs vaccines